1. Home
  2. CDNA vs VIR Comparison

CDNA vs VIR Comparison

Compare CDNA & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

N/A

Current Price

$37.52

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.35

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
VIR
Founded
1998
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
CDNA
VIR
Price
$37.52
$9.35
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$28.00
$19.43
AVG Volume (30 Days)
1.1M
1.9M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
0.05
N/A
Revenue
$48,324,000.00
$68,556,000.00
Revenue This Year
$16.01
$270.22
Revenue Next Year
$11.31
N/A
P/E Ratio
$752.20
N/A
Revenue Growth
18.93
N/A
52 Week Low
$11.26
$4.16
52 Week High
$40.47
$11.66

Technical Indicators

Market Signals
Indicator
CDNA
VIR
Relative Strength Index (RSI) 74.21 45.67
Support Level $15.89 $8.40
Resistance Level $40.47 $10.33
Average True Range (ATR) 1.65 0.43
MACD 0.56 -0.10
Stochastic Oscillator 84.19 15.65

Price Performance

Historical Comparison
CDNA
VIR

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: